Published in Cardiovasc Res on September 01, 2004
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol (2009) 5.28
Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med (2010) 3.26
Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A Biol Sci Med Sci (2010) 1.85
The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res (2010) 1.79
Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract (2006) 1.78
CD36: implications in cardiovascular disease. Int J Biochem Cell Biol (2007) 1.62
Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg (2009) 1.60
AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol (2011) 1.46
Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women. Aging Clin Exp Res (2009) 1.44
Oxidative stress and diabetes: what can we learn about insulin resistance from antioxidant mutant mouse models? Free Radic Biol Med (2011) 1.35
Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens (2008) 1.35
Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes (2015) 1.33
A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. J Proteome Res (2009) 1.31
Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis (2012) 1.28
Role of forkhead transcription factors in diabetes-induced oxidative stress. Exp Diabetes Res (2012) 1.27
Back to Wilson and Jungner: 10 good reasons to screen for type 2 diabetes mellitus. Mayo Clin Proc (2009) 1.26
Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam (2013) 1.22
Dietary advanced glycation end products and aging. Nutrients (2010) 1.16
Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci U S A (2006) 1.16
The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol (2008) 1.16
Complement-associated deposits in the human retina. Invest Ophthalmol Vis Sci (2008) 1.15
Neuronatin: a new inflammation gene expressed on the aortic endothelium of diabetic mice. Diabetes (2008) 1.13
Role of advanced glycation end products in cardiovascular disease. World J Cardiol (2012) 1.13
Diabetic Cardiovascular Disease Induced by Oxidative Stress. Int J Mol Sci (2015) 1.05
Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. J Am Geriatr Soc (2009) 1.03
A role for non-antimicrobial actions of tetracyclines in combating oxidative stress in periodontal and metabolic diseases: a literature review. Open Dent J (2008) 1.03
Involvement of inducible nitric oxide synthase in hydroxyl radical-mediated lipid peroxidation in streptozotocin-induced diabetes. Free Radic Biol Med (2008) 1.03
Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis (2008) 1.03
Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A (2015) 1.03
Apoptosis induction by oxidized glycated LDL in human retinal capillary pericytes is independent of activation of MAPK signaling pathways. Mol Vis (2009) 1.01
Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update. Acta Diabetol (2012) 1.00
Flow-dependent cellular mechanotransduction in atherosclerosis. J Cell Sci (2013) 1.00
Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. Eur J Heart Fail (2011) 0.99
Type 2 diabetes and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord (2011) 0.99
Post-ischemic inflammation regulates neural damage and protection. Front Cell Neurosci (2014) 0.97
Coronary microvascular dysfunction in diabetes mellitus: A review. World J Cardiol (2010) 0.96
Serum carboxymethyl-lysine, a dominant advanced glycation end product, is associated with chronic kidney disease: the Baltimore longitudinal study of aging. J Ren Nutr (2009) 0.94
Proinflammatory endothelial activation detected by molecular imaging in obese nonhuman primates coincides with onset of insulin resistance and progressively increases with duration of insulin resistance. Circulation (2013) 0.94
Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic subjects. J Proteome Res (2011) 0.93
Caloric restriction: implications for human cardiometabolic health. J Cardiopulm Rehabil Prev (2013) 0.93
Relationship of an advanced glycation end product, plasma carboxymethyl-lysine, with slow walking speed in older adults: the InCHIANTI study. Eur J Appl Physiol (2009) 0.92
Inflammatory cell phenotypes in AAAs: their role and potential as targets for therapy. Arterioscler Thromb Vasc Biol (2015) 0.90
Telomeres and atherosclerosis. Cardiovasc J Afr (2012) 0.89
Protein carbamylation is a hallmark of aging. Proc Natl Acad Sci U S A (2015) 0.89
Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression. Acta Pharmacol Sin (2010) 0.89
History of diabetes and risk of head and neck cancer: a pooled analysis from the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev (2011) 0.87
Functional decorations: post-translational modifications and heart disease delineated by targeted proteomics. Genome Med (2013) 0.87
Diabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculature. Front Endocrinol (Lausanne) (2013) 0.87
Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults. Eur J Nutr (2008) 0.86
Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. J Nutr (2014) 0.86
Serum amyloid A and inflammation in diabetic kidney disease and podocytes. Lab Invest (2014) 0.86
Vessel shrinkage as a sign of atherosclerosis progression in type 2 diabetes: a serial intravascular ultrasound analysis. Diabetes (2008) 0.86
Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions. Curr Diab Rep (2014) 0.86
Cell migration is regulated by AGE-RAGE interaction in human oral cancer cells in vitro. PLoS One (2014) 0.85
Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. Cardiovasc Diagn Ther (2014) 0.85
Antigen-induced immunomodulation in the pathogenesis of atherosclerosis. Clin Dev Immunol (2008) 0.85
Nerium oleander Distillate Improves Fat and Glucose Metabolism in High-Fat Diet-Fed Streptozotocin-Induced Diabetic Rats. Int J Endocrinol (2012) 0.85
Advanced Glycation End Products Enhance Macrophages Polarization into M1 Phenotype through Activating RAGE/NF-κB Pathway. Biomed Res Int (2015) 0.85
Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications. Genes Nutr (2007) 0.84
Diastolic dysfunction is associated with an increased risk of contrast-induced nephropathy: a retrospective cohort study. BMC Nephrol (2013) 0.84
Protein glycation inhibitory activity and antioxidant capacity of clove extract. J Food Sci Technol (2014) 0.84
Regulation of high-density lipoprotein on hematopoietic stem/progenitor cells in atherosclerosis requires scavenger receptor type BI expression. Arterioscler Thromb Vasc Biol (2014) 0.84
An advanced glycation end product (AGE)-receptor for AGEs (RAGE) axis restores adipogenic potential of senescent preadipocytes through modulation of p53 protein function. J Biol Chem (2012) 0.84
Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities. Open Dent J (2014) 0.83
Beta-thalassemia major and female fertility: the role of iron and iron-induced oxidative stress. Anemia (2013) 0.83
NOX enzymes and diabetic complications. Semin Immunopathol (2008) 0.83
Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: the Baltimore Longitudinal Study of Aging. J Nutr Health Aging (2010) 0.83
Advanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults. Atherosclerosis (2014) 0.82
Association of HbA1c and cardiovascular and renal disease in an adult Mediterranean population. BMC Nephrol (2013) 0.82
Resveratrol prevents dendritic cell maturation in response to advanced glycation end products. Oxid Med Cell Longev (2013) 0.82
Impact of protein energy wasting status on survival among Afro-Caribbean hemodialysis patients: a 3-year prospective study. Springerplus (2015) 0.82
The role of profilin-1 in endothelial cell injury induced by advanced glycation end products (AGEs). Cardiovasc Diabetol (2013) 0.82
Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT. Mediators Inflamm (2012) 0.81
Advanced glycation end-products induce apoptosis in pancreatic islet endothelial cells via NF-κB-activated cyclooxygenase-2/prostaglandin E2 up-regulation. PLoS One (2015) 0.81
Advanced glycation end products (AGEs) in relation to atherosclerotic lipid profiles in middle-aged and elderly diabetic patients. Lipids Health Dis (2011) 0.81
Selective Inhibition on RAGE-binding AGEs Required by Bioactive Peptide Alpha-S2 Case in Protein from Goat Ethawah Breed Milk: Study of Biological Modeling. Acta Inform Med (2015) 0.81
Molten globule of hemoglobin proceeds into aggregates and advanced glycated end products. PLoS One (2013) 0.81
Elevated serum advanced glycation end products and their circulating receptors are associated with anaemia in older community-dwelling women. Age Ageing (2009) 0.81
Reactive Oxygen Species, SUMOylation, and Endothelial Inflammation. Int J Inflam (2012) 0.80
Stem cells in the diabetic infarcted heart. Heart Fail Rev (2010) 0.80
Influence of insulin and muscle fiber type in nepsilon-(carboxymethyl)-lysine accumulation in soleus muscle of rats with streptozotocin-induced diabetes mellitus. Pathobiology (2009) 0.80
Changes in Structural-Mechanical Properties and Degradability of Collagen during Aging-associated Modifications. J Biol Chem (2015) 0.80
Antiatherosclerotic effect of korean red ginseng extract involves regulator of g-protein signaling 5. Evid Based Complement Alternat Med (2014) 0.79
Simultaneous noninvasive clinical measurement of lens autofluorescence and rayleigh scattering using a fluorescence biomicroscope. J Diabetes Sci Technol (2012) 0.79
Role of Src in Vascular Hyperpermeability Induced by Advanced Glycation End Products. Sci Rep (2015) 0.79
The role of triterpenes in the management of diabetes mellitus and its complications. Phytochem Rev (2014) 0.79
Effects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis. Br J Pharmacol (2014) 0.79
D-ribosylation induces cognitive impairment through RAGE-dependent astrocytic inflammation. Cell Death Dis (2014) 0.78
Combination of Medicinal Herbs KIOM-79 Reduces Advanced Glycation End Product Accumulation and the Expression of Inflammatory Factors in the Aorta of Zucker Diabetic Fatty Rats. Evid Based Complement Alternat Med (2011) 0.78
Automated quantification reveals hyperglycemia inhibits endothelial angiogenic function. PLoS One (2014) 0.78
Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? Ther Adv Urol (2009) 0.78
Influence of +1245 A/G MT1A polymorphism on advanced glycation end-products (AGEs) in elderly: effect of zinc supplementation. Genes Nutr (2014) 0.78
Diastolic function is reduced in adolescents with type 1 diabetes in response to exercise. Diabetes Care (2012) 0.78
Increased inflammation in atherosclerotic lesions of diabetic Akita-LDLr⁻/⁻ mice compared to nondiabetic LDLr⁻/⁻ mice. Exp Diabetes Res (2012) 0.78
HbA1c levels as predictors of ablation outcome in type 2 diabetes mellitus and paroxysmal atrial fibrillation. Herz (2014) 0.78
Glycated hemoglobin and its spinoffs: Cardiovascular disease markers or risk factors? World J Cardiol (2015) 0.77
Prognostic value of Diabetes in Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy. Sci Rep (2016) 0.77
The Role of Immunogenicity in Cardiovascular Disease. World Heart J (2011) 0.77
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Universal definition of myocardial infarction. Circulation (2007) 11.69
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation (2006) 5.31
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation (2002) 3.93
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11
Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension (2007) 2.90
Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology (2005) 2.74
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res (2003) 2.25
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res (2010) 2.19
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 2.18
Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2003) 2.17
The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation (2003) 2.14
Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab (2008) 2.13
RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J (2004) 2.08
S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem (2003) 2.05
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem (2008) 1.97
Identification, classification, and expression of RAGE gene splice variants. FASEB J (2007) 1.96
Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res (2008) 1.94
RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts. J Leukoc Biol (2009) 1.84
Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84
Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology (2004) 1.77
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther (2006) 1.77
Protein glycation: a firm link to endothelial cell dysfunction. Circ Res (2004) 1.76
RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis (2005) 1.67
Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci (2008) 1.67
Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res (2005) 1.64
Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med (2003) 1.62
Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci (2011) 1.60
Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg (2009) 1.60
Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J (2013) 1.60
Development of receptor for advanced glycation end products-directed imaging of atherosclerotic plaque in a murine model of spontaneous atherosclerosis. Circ Cardiovasc Imaging (2008) 1.58
Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev (2002) 1.56
The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci (2005) 1.55
Complete myocardial revascularization: between myth and reality. Eur Heart J (2005) 1.55
Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol (2004) 1.55
Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies. JACC Cardiovasc Interv (2013) 1.54
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. G Ital Cardiol (Rome) (2009) 1.52
RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) (2009) 1.52
Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) (2009) 1.51
Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation (2006) 1.48
Distal embolization during primary angioplasty: histopathologic features and predictability. Am Heart J (2005) 1.47
The adequacy of myocardial revascularization in patients with multivessel coronary artery disease. Int J Cardiol (2013) 1.45
Retracted Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes (2007) 1.44
RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum (2007) 1.44
Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Am Heart J (2004) 1.41
RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol (2008) 1.41
Imaging of receptors for advanced glycation end products in experimental myocardial ischemia and reperfusion injury. JACC Cardiovasc Imaging (2012) 1.40
Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol (2005) 1.39
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J (2009) 1.39
Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol (2003) 1.39
RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med (2007) 1.38
Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation (2003) 1.38
Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol (2006) 1.38
Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev (2002) 1.37
Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J Leukoc Biol (2007) 1.36
Arguing for the motion: yes, RAGE is a receptor for advanced glycation endproducts. Mol Nutr Food Res (2007) 1.35
RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J (2004) 1.35
RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med (2005) 1.35
The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med (2009) 1.35
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J (2004) 1.34
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J (2011) 1.34
AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol (2008) 1.32
Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes (2010) 1.32
The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. Proc Natl Acad Sci U S A (2006) 1.32
Mechanisms for the induction of HNE- MDA- and AGE-adducts, RAGE and VEGF in retinal pigment epithelial cells. Exp Eye Res (2005) 1.31
Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep (2002) 1.30
Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol (2003) 1.30
Recommendations for the management of patients after heart valve surgery. Eur Heart J (2005) 1.29
RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. Am J Physiol Heart Circ Physiol (2008) 1.29
At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol (2005) 1.27
Early growth response-1 promotes atherogenesis: mice deficient in early growth response-1 and apolipoprotein E display decreased atherosclerosis and vascular inflammation. Circ Res (2003) 1.27
Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. J Immunol (2007) 1.26
RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol (2002) 1.25
Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med (2009) 1.25
RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol (2008) 1.24
Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch Biochem Biophys (2012) 1.24
Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J (2009) 1.23